The potential forRadius Health Inc.'s abaloparatide to better improve hip bone mass and have a lower risk of hypercalcemia than earlier osteoporosis drugs "may be important distinguishing features," a new editorial in the Journal of the Medical Association concludes, but the article also suggests this may not be enough for commercial success.
The editorial – by Anne Cappola, University of Pennsylvania, and Dolores Shoback, University of California-San Francisco – was published in...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)